FDA targets faster generic approvals in drive to slash drug prices

Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech

5 October 2026 Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection.

Regulation & Industry

5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?

1 October 2026 LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.

Regulation & Industry

Westlaw publisher scores landmark AI copyright win in US appeals court

30 September 2026 The Third Circuit has upheld Thomson Reuters’ victory over Ross Intelligence in the first US appellate ruling on whether AI training can qualify as fair use. With the court’s reasoning still sealed, the case could have significant implications for AI developers using copyrighted content to build competing products.

More features

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech

Fish & Richardson nets patent litigator to grow European practice

What's AI best at? In-house teams are still learning

WATCH: Genevant IP director on tackling UPC-EPO opposition divide

5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?

Lilly loses Fed Circ rehearing bid, sparking enablement questions

FDA targets faster generic approvals in drive to slash drug prices

More on this story

Editor's picks

Editor's picks

More features